FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283696527> ?p ?o ?g. }

• W4283696527 endingPage "3776" @default.
• W4283696527 startingPage "3766" @default.
• W4283696527 abstract "The direct oral anticoagulant (DOAC) apixaban has shown to have non-inferior efficacy and better safety than vitamin K antagonists (VKAs) in patients with venous thromboembolism (VTE). We determined whether healthcare resource use (HCRU) and direct all-cause medical and non-medical costs in patients with VTE in France differed between VKAs and apixaban.A retrospective cohort study was conducted using French national health data from January 2013-June 2018 for anticoagulant-naïve adults hospitalized with VTE. All-cause costs and HCRU per patient per month (PPPM) were compared between apixaban and VKA cohorts created by 1:1 propensity score matching. Two-part models with bootstrapping were used to calculate marginal effects for costs and HCRU.The matched VKA and apixaban cohorts each comprised 7503 patients. Compared to VKAs, patients prescribed apixaban had significantly lower (P < 0.0001) mean all-cause costs PPPM for outpatient visits (€438.54 vs. €455.58), overall laboratory tests (€21.26 vs. €83.73), and hospitalizations (€249.48 vs. €343.82), but significantly higher (P < 0.0001) mean all-cause costs PPPM for overall drugs (€97.06 vs. €69.56) and medical procedures (€42.12 vs. €35.50). Mean total all-cause direct medical costs (€687.93 vs. €798.70) and total all-cause direct medical and non-medical costs (€771.60 vs. €883.66) were significantly lower (P < 0.0001) for apixaban. Mean HCRU PPPM showed similar trends. Subgroup analyses showed that, among patients with recurrent VTE, patients prescribed apixaban had significantly lower (P < 0.0001) all-cause costs PPPM for total medical costs (€17.26 vs. €18.12) and total all-cause direct medical and non-medical costs (€18.37 vs. €19.20) than patients prescribed VKAs. Similarly, among patients with bleeding, patients prescribed apixaban had significantly lower (P < 0.0001) all-cause costs PPPM for total medical costs (€15.34 vs. €32.61) and total all-cause direct medical and non-medical costs (€16.23 vs. €34.63) than patients prescribed VKAs.Compared to VKAs, apixaban may be cost-saving in the treatment of patients hospitalized for acute VTE." @default.
• W4283696527 created "2022-06-30" @default.
• W4283696527 creator A5007114290 @default.
• W4283696527 creator A5008339206 @default.
• W4283696527 creator A5025681291 @default.
• W4283696527 creator A5026174340 @default.
• W4283696527 creator A5047153009 @default.
• W4283696527 creator A5084480834 @default.
• W4283696527 date "2022-06-29" @default.
• W4283696527 modified "2023-10-04" @default.
• W4283696527 title "Comparative Analysis of All-Cause Health Care Resource Utilization and Costs Among Venous Thrombosis Patients Without Cancer Prescribed Apixaban or VKAs in France" @default.
• W4283696527 cites W1166257575 @default.
• W4283696527 cites W1494928676 @default.
• W4283696527 cites W2166402206 @default.
• W4283696527 cites W2171381436 @default.
• W4283696527 cites W2181066222 @default.
• W4283696527 cites W2225937646 @default.
• W4283696527 cites W2274890744 @default.
• W4283696527 cites W2279529838 @default.
• W4283696527 cites W2528604229 @default.
• W4283696527 cites W2581509534 @default.
• W4283696527 cites W2582661577 @default.
• W4283696527 cites W263154455 @default.
• W4283696527 cites W2898556438 @default.
• W4283696527 cites W2923408498 @default.
• W4283696527 cites W2945624711 @default.
• W4283696527 cites W2965349762 @default.
• W4283696527 cites W2971121646 @default.
• W4283696527 cites W2972662720 @default.
• W4283696527 cites W2998804198 @default.
• W4283696527 cites W3002298057 @default.
• W4283696527 cites W3007833288 @default.
• W4283696527 cites W3090209681 @default.
• W4283696527 cites W4205523407 @default.
• W4283696527 cites W4296148784 @default.
• W4283696527 doi "https://doi.org/10.1007/s12325-022-02200-7" @default.
• W4283696527 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35767124" @default.
• W4283696527 hasPublicationYear "2022" @default.
• W4283696527 type Work @default.
• W4283696527 citedByCount "1" @default.
• W4283696527 countsByYear W42836965272023 @default.
• W4283696527 crossrefType "journal-article" @default.
• W4283696527 hasAuthorship W4283696527A5007114290 @default.
• W4283696527 hasAuthorship W4283696527A5008339206 @default.
• W4283696527 hasAuthorship W4283696527A5025681291 @default.
• W4283696527 hasAuthorship W4283696527A5026174340 @default.
• W4283696527 hasAuthorship W4283696527A5047153009 @default.
• W4283696527 hasAuthorship W4283696527A5084480834 @default.
• W4283696527 hasBestOaLocation W42836965271 @default.
• W4283696527 hasConcept C121955636 @default.
• W4283696527 hasConcept C126322002 @default.
• W4283696527 hasConcept C144133560 @default.
• W4283696527 hasConcept C167135981 @default.
• W4283696527 hasConcept C17923572 @default.
• W4283696527 hasConcept C194828623 @default.
• W4283696527 hasConcept C201903717 @default.
• W4283696527 hasConcept C2776301958 @default.
• W4283696527 hasConcept C2778661090 @default.
• W4283696527 hasConcept C2779161974 @default.
• W4283696527 hasConcept C2780638905 @default.
• W4283696527 hasConcept C6964187 @default.
• W4283696527 hasConcept C71924100 @default.
• W4283696527 hasConcept C72563966 @default.
• W4283696527 hasConceptScore W4283696527C121955636 @default.
• W4283696527 hasConceptScore W4283696527C126322002 @default.
• W4283696527 hasConceptScore W4283696527C144133560 @default.
• W4283696527 hasConceptScore W4283696527C167135981 @default.
• W4283696527 hasConceptScore W4283696527C17923572 @default.
• W4283696527 hasConceptScore W4283696527C194828623 @default.
• W4283696527 hasConceptScore W4283696527C201903717 @default.
• W4283696527 hasConceptScore W4283696527C2776301958 @default.
• W4283696527 hasConceptScore W4283696527C2778661090 @default.
• W4283696527 hasConceptScore W4283696527C2779161974 @default.
• W4283696527 hasConceptScore W4283696527C2780638905 @default.
• W4283696527 hasConceptScore W4283696527C6964187 @default.
• W4283696527 hasConceptScore W4283696527C71924100 @default.
• W4283696527 hasConceptScore W4283696527C72563966 @default.
• W4283696527 hasFunder F4320307115 @default.
• W4283696527 hasFunder F4320307765 @default.
• W4283696527 hasIssue "8" @default.
• W4283696527 hasLocation W42836965271 @default.
• W4283696527 hasLocation W42836965272 @default.
• W4283696527 hasLocation W42836965273 @default.
• W4283696527 hasOpenAccess W4283696527 @default.
• W4283696527 hasPrimaryLocation W42836965271 @default.
• W4283696527 hasRelatedWork W1918795463 @default.
• W4283696527 hasRelatedWork W1971557041 @default.
• W4283696527 hasRelatedWork W2384980663 @default.
• W4283696527 hasRelatedWork W2538561576 @default.
• W4283696527 hasRelatedWork W2999114503 @default.
• W4283696527 hasRelatedWork W3092529470 @default.
• W4283696527 hasRelatedWork W3213271392 @default.
• W4283696527 hasRelatedWork W4205338151 @default.
• W4283696527 hasRelatedWork W4235834539 @default.
• W4283696527 hasRelatedWork W4386698608 @default.
• W4283696527 hasVolume "39" @default.
• W4283696527 isParatext "false" @default.
• W4283696527 isRetracted "false" @default.

• next